Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to assess the safety and efficacy (the percentage of subjects with HCV RNA <LLOG 12 weeks after the last actual dose of study drug (SVR12 actual)) of ABT-450/r and ABT-267 among HCV subjects as specified in the Substudies 1 and 2 objectives below.
Critère d'inclusion
- Chronic Hepatitis C Infection